Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman.

A large prospective study suggests pro-inflammatory diets may increase risk of death in patients with stage III colon cancer, ...

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

A review of 22 trials led the American Society of Clinical Oncology (ASCO) to issue updates to its mCRPC systemic therapy ...

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...